These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15221995)

  • 1. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
    Burger RA; Darcy KM; DiSaia PJ; Monk BJ; Grosen EA; Gatanaga T; Granger GA; Wang J; Tian C; Hanjani P; Cohn DE
    Cancer; 2004 Jul; 101(1):106-15. PubMed ID: 15221995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Gagetti O; Prontera C; Bianchi R; Facchini V
    Gynecol Oncol; 1995 Aug; 58(2):184-8. PubMed ID: 7542621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.
    Kolwijck E; Span PN; Thomas CM; Bulten J; Sweep FC; Massuger LF
    Oncol Rep; 2010 Feb; 23(2):579-84. PubMed ID: 20043124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy.
    Grosen EA; Granger GA; Gatanaga M; Ininns EK; Hwang C; DiSaia P; Berman M; Manetta A; Emma D; Gatanaga T
    Gynecol Oncol; 1993 Jul; 50(1):68-77. PubMed ID: 8394276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
    J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
    ; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
    Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
    Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
    Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
    Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
    Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
    Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
    J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Secord AA; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A;
    Gynecol Oncol; 2007 Jul; 106(1):221-32. PubMed ID: 17481705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.
    Kang S; Seo SS; Park SY
    J Surg Oncol; 2009 Sep; 100(3):244-7. PubMed ID: 19267361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer.
    Koh SC; Razvi K; Chan YH; Narasimhan K; Ilancheran A; Low JJ; Choolani M;
    Arch Gynecol Obstet; 2011 Jul; 284(1):183-90. PubMed ID: 20680316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum levels of soluble tumor necrosis factor receptors as markers for disease progression of human immunodeficiency virus infection].
    Hattori M; Tateyama M; Oishi T; Miyasaka S; Fukutake K
    Rinsho Byori; 1997 Nov; 45(11):1085-90. PubMed ID: 9396350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.